Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Quick Facts
What This Study Found
At week 40, mean HbA1c change was -2.40% with 10 mg tirzepatide vs -0.86% with placebo (P < .001).
Key Numbers
How They Did This
A randomized phase 3 clinical trial with 475 participants, comparing tirzepatide doses to placebo over 40 weeks.
Why This Research Matters
These results indicate that tirzepatide can be an effective addition to insulin therapy for better blood sugar control in type 2 diabetes. This could lead to improved patient outcomes and management strategies.
What This Study Doesn't Tell Us
The study was limited to a specific population and duration, and long-term effects of tirzepatide remain to be evaluated.
Trust & Context
- Original Title:
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
- Published In:
- JAMA, 327(6), 534-545 (2022)
- Authors:
- Dahl, Dominik, Onishi, Yukiko, Norwood, Paul, Huh, Ruth, Bray, Ross, Patel, Hiren, Rodríguez, Ángel
- Database ID:
- RPEP-06073
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06073APA
Dahl, Dominik; Onishi, Yukiko; Norwood, Paul; Huh, Ruth; Bray, Ross; Patel, Hiren; Rodríguez, Ángel. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.. JAMA, 327(6), 534-545. https://doi.org/10.1001/jama.2022.0078
MLA
Dahl, Dominik, et al. "Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.." JAMA, 2022. https://doi.org/10.1001/jama.2022.0078
RethinkPeptides
RethinkPeptides Research Database. "Effect of Subcutaneous Tirzepatide vs Placebo Added to Titra..." RPEP-06073. Retrieved from https://rethinkpeptides.com/research/dahl-2022-effect-of-subcutaneous-tirzepatide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.